Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide with Temozolomide in Newly Diagnosed MGMT-Methylated IDH Wildtype Glioblastoma
NCT03011671Phase 1Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Oct 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acetazolamide in glioblastoma (GBM) and astrocytoma, sponsored by University of Chicago. Primary endpoint: Number of participants with adverse events at 28 days. Started Oct 2018; status: active, not recruiting.
02
Drugs
acetazolamide
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT03011671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011671.